A new collaborative effort between Mayo Clinical Laboratories and Amprion will expand access to the diagnostic company’s SAAmplify–αSYN test — designed to detect the presence of abnormal alpha-synuclein protein in people suspected of having neurodegenerative diseases — across the U.S., according to a joint press release.
Researchers at the University of Delaware have developed a model that combines artificial intelligence with magnetic resonance elastography (MRE) to measure brain stiffness and volume for predicting brain age. MRE is a noninvasive method that can measure changes in brain stiffness by using a gentle vibration of a person’s head…
Newronika is preparing for the commercial launch of AlphaDBS — a next-generation adaptive deep brain stimulation (DBS) system for treating Parkinson’s disease — at selected markets in Europe this year, following CE Mark approval in the European Union. That’s according to a company press release, in which…
Neuropacs‘ MRI-based artificial intelligence (AI) technology demonstrated 96% accuracy in distinguishing Parkinson’s disease from atypical parkinsonism — including multiple system atrophy, known as MSA, and progressive supranuclear palsy, called PSP — the company announced, detailing the results of a federally funded U.S. study. Moreover, the system achieved 98%…
Parkinson Italia — a network of 30 associations for patients and caregivers in Italy — is backing an initiative by the Prada Foundation that seeks to highlight the importance of prevention and early treatment of neurodegenerative diseases like Parkinson’s. The campaign, dubbed Preserving the Brain: A…
Most people with early-stage Parkinson’s disease have sleep disturbances, with many having more than one at the same time, a study in France suggests. Sleep disorders were mainly associated with body changes, including motor symptoms and problems regulating involuntary bodily functions, rather than depression or anxiety. “The timely…
Angels on Call, a home care services provider, has been recognized as a Community Partner in Parkinson’s Care by the Parkinson’s Foundation. The Community Partner in Parkinson’s Care membership program educates and trains staff to deliver care plans specifically focused on Parkinson’s patient’s symptoms and…
A researcher at the University of Wollongong in Australia has received funding of nearly 400,000 Australian dollars (about $250,000) to investigate the links between environmental toxins, such as pesticides and nanoplastics, and Parkinson’s disease. The funding, from The Michael J. Fox Foundation for Parkinson’s Research and the…
Among people with rapid eye movement (REM) sleep behavior disorder, blood biomarkers associated with dementia may help identify those at risk of developing Dementia with Lewy Bodies (DLB), a condition that shares symptoms with Parkinson’s disease. Particularly, blood levels of two proteins — amyloid-beta 42/40 ratio and p-tau…
A Phase 2a clinical trial testing Ventus Therapeutics’ VENT-02 — a novel brain-penetrating oral medication — in adults with mild to moderate Parkinson’s disease has dosed its first patient. The study (NCT06822517), expected to enroll about 30 people with Parkinson’s, is assessing the treatment’s safety, tolerability, effects on…
Get regular updates to your inbox.
